---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-029221"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:58:33.435009+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AVROBIO completes $87.5M sale of cystinosis gene therapy program to Novartis; cash runway extended to Q4 2024

## Summary
- Sale closed June 9, 2023 for $87.5M cash; proceeds expected to extend cash runway into Q4 2024.
- AVROBIO retains full rights to HSC gene therapy programs for Gaucher, Hunter, and Pompe diseases.
- Term Loan Facility with Silicon Valley Bank repaid in full and terminated upon closing.
- Interim CEO Ostrowski gets base salary increase to $535K, 55% bonus target, and 70,000 RSUs; retention bonuses approved for Ostrowski and CTO Golipour.
- Unaudited pro forma shows net loss improved to $23.7M for Q1 2023 and $16.8M for FY2022 including gain on asset sale.

## SEC filing metadata
- accession: 0001140361-23-029221
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 2.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036123029221/0001140361-23-029221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036123029221/brhc20054252_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-029221
- JSON: https://secwatch.observer/filing/0001140361-23-029221.json
- Plain text: https://secwatch.observer/filing/0001140361-23-029221.txt

## Key facts
- M&A Transactions
  Tectonic Therapeutic, Inc. completed a disposition involving Novartis Pharma AG and Novartis Pharmaceuticals Corporation for $87.5 million (closed 2023-06-09).
  - Action: disposition
  - Counterparty: Novartis Pharma AG and Novartis Pharmaceuticals Corporation
  - Consideration: $87.5 million
  - Closing: 2023-06-09
  source text: Hunter syndrome and Fabry disease, or indemnification claims under the Asset Purchase Agreement. The aggregate consideration to the Company consists of a cash payment of $87.5 million upon closing of the transaction on June 9, 2023 (the “Closing Date”). The Asset Purchase Agreement contains certain customary representations, warranties and covenants. The Asset
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681087/000114036123029221/0001140361-23-029221-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.